Day: November 17, 2025

Hong Kong, Nov. 17, 2025 (GLOBE NEWSWIRE) — Click Holdings Limited (“Click Holdings” or “Click” or “we” or “us”, NASDAQ: CLIK) and its subsidiaries (collectively, the “Company”), Hong Kong’s only Nasdaq-listed leader in human resources and senior care solutions, announced to acquire 100% equity interest in Bowser Human Resources Limited (“Bowser”) and Top Team Consultants Limited (“Top Team”), being two Hong Kong-based human resources solutions providers operating in the region, by the issuance of 1,885,350 and 232,256 Class A ordinary shares of the Company respectively. These acquisitions will supercharge Click’s strategic growth, unlock synergies, and propel the Company to new heights of market dominance by further solidifying our fast-growing talent pools. “These acquisitions affirm our ambition to continue expanding our presence...

WILMINGTON, Del., Nov. 17, 2025 (GLOBE NEWSWIRE) — Clover Health Investments, Corp. (Nasdaq: CLOV) (“Clover,” “Clover Health” or the “Company”), today announced that its Chief Financial Officer, Peter Kuipers, will present at the 2025 Citi Global Healthcare Conference on Thursday, December 4, 2025, at 11:15 a.m. Eastern Time. A live webcast and replay of the presentation will be accessible on Clover Health’s investor relations website at https://investors.cloverhealth.com/. About Clover Health:Clover Health (Nasdaq: CLOV) is a physician enablement technology company committed to bringing access to great healthcare to everyone on Medicare. This includes a focus on seniors who have historically lacked access to affordable, high-quality healthcare. Our strategy is powered by our software platform, Clover Assistant, which is...

MALVERN, Pa., Nov. 17, 2025 (GLOBE NEWSWIRE) — TELA Bio, Inc. (“TELA Bio”) (NASDAQ: TELA), a commercial-stage medical technology company focused on providing innovative soft-tissue reconstruction solutions, today announced that the Compensation Committee of the Board of Directors of TELA Bio approved inducement grants of (i) restricted stock units covering 30,200 shares of its common stock to seventeen newly-hired employees and (ii) an option to purchase 25,000 shares of its common stock to one employee, with a grant date of November 10, 2025 (the “Grant Date”). The equity awards were granted pursuant to the Nasdaq Rule 5635(c)(4) inducement grant exception as a component of each individual’s employment compensation and were granted as an inducement material to his or her acceptance of employment with...

Largest real-world analysis of AI-driven breast cancer screening in U.S. history1 demonstrates increased cancer detection rate with consistent benefits across patient populations LOS ANGELES and SOMERVILLE, Mass., Nov. 17, 2025 (GLOBE NEWSWIRE) — RadNet, Inc. (NASDAQ: RDNT), the nation’s largest provider of outpatient diagnostic imaging services, and its wholly owned subsidiary, DeepHealth, a global leader in AI-powered health informatics, today announced results from the largest real-world analysis of AI-driven breast cancer screening ever conducted in the United States.1 Published in Nature Health, the findings support the clinical effectiveness and benefit of DeepHealth’s AI technology to deliver equitable results across several racial, ethnic and breast density patient groups. The AI-Supported Safeguard Review Evaluation...

NEEDHAM, Mass., Nov. 17, 2025 (GLOBE NEWSWIRE) — Candel Therapeutics, Inc. (Candel or the Company) (Nasdaq: CADL), a clinical-stage biopharmaceutical company focused on developing multimodal biological immunotherapies to help patients fight cancer, today announced it will host a virtual Research and Development (R&D) Event from 11:00 am – 1:45 pm ET on Friday, December 5, 2025. Candel’s R&D Day will include presentations and panel discussions from its executive leadership, clinical investigators, scientific advisors, and key collaborators. The event will provide an extensive overview of the Company’s viral immunotherapy approach and oncology-focused pipeline. Click here to register for the event. The R&D Day will include the following presentations: Introduction to Candel Therapeutics: Paul Peter Tak, MD, PhD, FMedSci,...

MINNEAPOLIS, Nov. 17, 2025 (GLOBE NEWSWIRE) — Celcuity Inc. (Nasdaq: CELC), a clinical-stage biotechnology company pursuing development of targeted therapies for oncology, today announced the completion of the submission of its New Drug Application (“NDA”) to the U.S. Food and Drug Administration (“FDA”) for gedatolisib in hormone receptor positive (“HR+”), human epidermal growth factor receptor 2 negative (“HER2-”), advanced breast cancer (“ABC”). The NDA was submitted under the FDA’s Real-Time Oncology Review (“RTOR”) program, which is intended to facilitate shorter regulatory review periods. Gedatolisib previously received both Breakthrough Therapy and Fast Track designations based on promising preliminary clinical data. The submission is based on clinical data from the PIK3CA wild-type cohort of the Phase 3 VIKTORIA-1 clinical...

CLEARWATER Fla., Nov. 17, 2025 (GLOBE NEWSWIRE) — Apyx Medical Corporation (Nasdaq: APYX) (the “Company” or “Apyx Medical”) the leader in surgical aesthetics marketed and sold as Renuvion® and the AYON Body Contouring System™ (AYON), today announced that it is commencing an underwritten public offering of shares of its common stock (or common stock equivalents). The offering is subject to market conditions, and there can be no assurance as to whether or when the offering may be completed, or as to the actual size or terms of the offering. Lucid Capital Markets is acting as the sole book-running manager for the offering. The offering is being made pursuant to a shelf registration statement on Form S-3 (File No. 333-268532) filed with the Securities and Exchange Commission (“SEC”) on November 22, 2022, and declared effective...

A high-quality portfolio consisting of North American Financial Services Companies TORONTO, Nov. 17, 2025 (GLOBE NEWSWIRE) — Financial 15 Split Corp. (the “Company”) is pleased to announce it will undertake an offering of Preferred Shares (TSX: FTN.PR.A) of the Company. The offering will be led by National Bank Financial Inc. The sales period of this overnight offering will end at 9:00 a.m. EST on November 18, 2025. The offering is expected to close on or about November 25, 2025 and is subject to certain closing conditions including approval by the TSX. The Preferred Shares will be offered at a price of $10.60 per Preferred Share. The closing price on the TSX of the Preferred Shares on November 14, 2025 was $10.72. Since the inception of the Company, 263 consecutive dividends have been declared for the Preferred Shares. The aggregate...